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Summary In a non-randomised study in six centres in the UK, 24 patients with previously untreated
small-cell lung cancer of limited extent were treated with a regimen of alternating chemotherapy and
radiotherapy to assess response, toxicity, and the feasibility of applying such a regimen on a multicentre basis
in the UK. The intention was to give six courses ofchemotherapy on five consecutive days at 4-week intervals:
etoposide 75 mg m2 on days 1, 2, and 3; doxorubicin 40mgm2 on day 1; cisplatin 100mgm2 on day 2;
and cyclophosphamide 300 mg m-2 on days 2, 3, 4 and 5. A dose of 20 Gy thoracic radiotherapy was to be
given following the 2nd and the 3rd courses, and one of 15 Gy following the 4th course. After 12 patients had
been admitted, the cisplatin dosage was reduced to 80 mg m-2 because of unacceptable toxicity. Two patients
were withdrawn during treatment on review of their histology because their diagnosis was found to be
incorrect. Only one patient of the 12 treated with cisplatin 100 mgm2 was able to complete treatment,
compared with five of the eligible ten given the lower dosage. Among the 22 patients with confirmed small-cell
disease, a complete response was reported in 14 (64%) and a partial response in a further three (total response
rate 77%). Myelosuppression was the commonest serious adverse effect. It occurred in 19 of the 24 patients
and gave rise to septicaemia in five, four of whom were receiving the higher cisplatin dose. Sixteen patients
required blood transfusion and ten platelet transfusion. Vomiting, oesophagitis, and peripheral neuropathy
occurred in 12, four and four patients, respectively, and radiation pneumonitis developed in two. Treatment
was considered a contributory cause of death in four. The working party concluded that the alternating
regimen was feasible in only a small proportion of centres in the UK, and decided not to embark on a
multicentre randomised trial comparing alternating with conventional scheduling.
Small-cell lung cancer responds well to combination chemo-
therapy (Seifter & Ihde, 1988). Objective response rates
(World Health Organization, 1979) of around 80% are typi-
cal in published reports, as are median survival times of
approximately 12 months in patients with limited disease and
6 months in those with extensive disease (Leonard, 1989). In
patients with limited disease, the inclusion of thoracic radio-
therapy in the treatment regimen both improves local control
of the cancer and prolongs survival (Bleehen, 1986; Arria-
gada et al., 1989a). Nevertheless, 3-year survival rates are
low and the great majority of patients die from their lung
cancer.
At the time this study was planned, however, not only high
response rates but also substantial 2-year and 3-year survival
rates were being reported by Arriagada and his colleagues in
non-randomised phase II trials using regimens of alternating
chemotherapy and radiotherapy. Thirty-five patients less than
70 years of age, with small-cell lung cancer of limited extent,
and good performance status, were treated with a regimen of
three doses of mediastinal radiotherapy (total dose, 55 Gy)
and six courses of chemotherapy using doxorubicin, etopo-
side, cyclophosphamide, and cisplatin. The radiotherapy was
given following the 2nd, the 3rd, and the 4th courses of
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chemotherapy which were given at 4-week intervals (Arria-
gada et al., 1985a). The complete response rate, broncho-
scopically confirmed, was 91%, the local recurrence rate
was 22%, and the relapse-free survival rate at 2 years was
32%. Haematological toxicity, oesophagitis, and infectious
bronchopneumonia were common, but were considered
acceptable. Subsequently, in 109 similarly treated patients (Le
Chevalier et al., 1987), the complete response rate was 79%,
the local recurrence rate was 25%, and the survival rate at 3
years was 26%. Lethal toxicity was reported in 3% of the
patients.
It therefore appeared that alternating scheduling might
improve long-term survival rates, although the patients
selected for the above trials were a group known to have a
relatively good prognosis (Rawson & Peto, 1990).
The rationale for alternating the chemotherapy and radio-
therapy is to make optimum use of these two modalities from
the start of treatment, without incurring the unacceptable
levels of toxicity that have been reported when the two are
given concurrently (Arriagada et al., 1985b; 1989a; Bunn et
al., 1987). Early use of both modalities rapidly reduces
tumour bulk, and is presumed to lessen the risk of the
emergence of resistant cells. Early use of chemotherapy
ensures that occult distant metastases are suppressed from
the start, and an alternating schedule allows the chemo-
therapy to be given without interruption in regular (4-weekly)
courses.
The present trial was conducted to determine whether the
regimen used by Arriagada and his colleagues was logistically
feasible in centres in the United Kingdom, whether the toxi-
city was acceptable, and whether high complete response
rates could be achieved. The intention was that a large
multicentre randomised trial to compare alternating with
conventional scheduling should then be considered.
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Methods
Eligibility
Eligible patients were of either sex, aged 70 years or less.
They had previously untreated, small-cell lung cancer, diag-
nosed according to WHO criteria (World Health Organiza-
tion, 1981), which was limited clinically and radiographically
to the soft tissues of one hemithorax, the mediastinum and
the ipsilateral and contralateral scalene and lower cervical
lymph nodes, and was encompassable by the radiation
volume. They had to have a good performance status, name-
ly to be ambulatory, capable of all self-care, and up and
about more than 50% of waking hours (grade 0-2, World
Health Organization, 1979), and to have normal renal and
liver function. Local ethics committee approval of the proto-
col and individual patient consent were required.
Treatment
All the patients were prescribed the same regimen of alter-
nating chemotherapy and radiotherapy (Figure 1). The inten-
tion was to give six courses of chemotherapy, with diuresis,
on an inpatient basis during five consecutive days at 4-week
intervals, and three courses of radiotherapy: the first two
over 12 days following the 2nd and the 3rd course of chemo-
therapy, and the 3rd over 10 days following the 4th course of
chemotherapy. There were intervals of between 5 and 7 days
between consecutive courses of chemotherapy and radio-
therapy.
Chemotherapy Etoposide 75 mg m-2 was given by intra-
venous infusion over 30 min on days 1, 2 and 3; doxorubicin
40 mg m-2 by intravenous injection on day 1 ; cisplatin
100 mg m-2 by intranvenous injection on day 2; and cyclo-
phosphamide 300 mg m-2 by intravenous injection on days 2,
3, 4 and 5. After 12 patients had been admitted, the cisplatin
dosage was reduced from 100 to 80 mg m-2, because of
excessive toxicity.
Radiotherapy Megavoltage radiotherapy was given using
planned fields to all visible tumour with a 1.5 cm margin
(based on the pre-chemotherapy volume) of normal tissue, as
well as to the mediastinum, both lung hila and supraclavi-
cular regions. It was given in fractions of 2 Gy five times per
week. Twenty Gy (ten fractions) was given following the 2nd
and the 3rd course of chemotherapy, and 15 Gy (seven frac-
tions of 2 Gy, one of 1 Gy) following the 4th course. The
first two doses were given through opposed anteroposterior
fields, the third through lateral fields avoiding the spinal
cord.
was completed at each attendance for chemotherapy or
radiotherapy, giving details of the treatment given, the
response to treatment (World Health Organization, 1979),
and adverse reactions encountered. The above blood tests
were repeated, and chest radiography and an electrocardio-
gram were done. When appropriate, bronchoscopy, marrow
histology, and the scans were repeated at the end of treat-
ment. Chest radiography was repeated 3 weeks after the end
of the last course of chemotherapy.
Results
Patients in the study
Between June 1988 and March 1989 12 patients were admit-
ted to the study from six centres in the United Kingdom, and
were prescribed the regimen with a cisplatin dosage of
100 mgmA2. Between March 1989 and November 1989, a
further 12 patients were admitted and were prescribed the
lower cisplatin dosage of 80mgm-'.
Nineteen of the 24 patients were men (Table I). On admis-
sion, 18 were aged less than 60 years, and 20 had a normal
or near normal performance status (grade 0 or 1). The
staging procedures included bronchoscopy in all except two,
and bone radio-isotope scan, marrow histology, and CT scan
of the chest in the majority.
Treatment received
The calculated drug dosages (mgm2) actually received by
the 24 patients in their first course of chemotherapy ranged
from 69.1 to 77.5 (mean 74.1) for etoposide, 32.6 to 41.3
(mean 39.2) for doxorubicin, and 278.9 to 310.1 (mean 295.7)
for cyclophosphamide; the cisplatin dosage ranged from 98.5
to 101.3 (mean 99.8) in the 12 patients assigned to receive
100, and from 73.4 to 82.7 (mean 79.0) in the 12 patients
assigned to receive 80. Thus, in all patients, the dosages
prescribed were very close to the protocol dosages.
In Table II the patients are ranked according to the
amount of treatment received. Of the 12 treated with cis-
platin 100 mg -2, only one (patient 1) received all six courses
of chemotherapy and all three doses of radiotherapy. The
next six received all three doses of radiotherapy, but only
five, four or three courses of chemotherapy, because of toxi-
city. The remaining five patients received only three or one
course ofchemotherapy and three of them received no radio-
therapy at all; in three of the five this was because they died,
Reports and investigations
The pretreatment investigations included a thorough clinical
examination, chest radiography, measurement of the blood
haemaglobin and plasma urea and creatinine concentrations,
and total blood white cell and platelet counts, and, whenever
possible, bronchoscopy, liver ultrasound scan, bone radio-
isotope scan, marrow trephine biopsy and aspiration, and CT
scan of chest, brain, and abdomen. A report on each patient
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Figure 1 Scheduling of the chemotherapy and
radiotherapy El. Each course of chemotherapy lasted 5 days.
The 20 Gy doses of radiotherapy were given over 12 days and the
15 Gy dose over 10 days, allowing for 2 days (a week-end) during
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received ofsurvival Reason treatment
Patient Centre CT RT Responsea (days)b Main adverse effects not completed
Cisplatin 100 mg m 2
1 A 6 3 CR 706 + Myelosuppression
2 B 5 3 CR 1022 + Oesophagitis, myelosuppression, neuropathy,
bleeding, pneumonitis Toxicity
3 B 5 3 CR 275 Mucositis, mylesuppression, septicaemia Toxicity
4 B 5 3 CR 444 Myleosuppression, septicaemia, vomiting Toxicity
5 C 4 3 PR 333 Oesophagitis, myelosuppression, fever
vomiting Toxicity
6 C 4 3 CR 277 Vomiting, myelosuppression, fever Toxicity
7 D 3 3 CR 808 Vomiting, myelosuppression, loss of taste Toxicity
8 B 3 2 CR 912 + Vomiting, myelosuppression, septicaemia
impaired renal function Toxicity
9 E 1 1 PR 308 Myleosuppression, fever, jaundice Progression
10 B 1 0 nil 21 Myelosuppression, septicaemia
bronchopneumonia Death
11 C 1 0 nil 4 Sudden collapse and death Death
12 D 1 0 nil 18 Bronchopneumonia Death
Cisplatin 80 mg m-2
13 D 6 3 CR 790 + Vomiting, oesophagitis
14 F 6 3 CR 554 Vomiting, mucositis, myelosuppression
neuropathy, diarrhoea
15 F 6 3 CR 578 + Vomiting, myelosuppression, oral candidiasis
pneumonitis, rash, neuropathy, diarrhoea -
16 B 6 3 CR 440 + Skin reaction to radiotherapy,
myelosuppression
17 A 6 3 PR 325 Myelosuppression, septicaemia
18 B 5 3 CR 248 Myelosuppression, neuropathy, impaired
renal function, vomiting Toxicity
19 B 5 3 CR 287 Mouth ulcers, impaired renal function,
myelosuppression, oesophageal candidiasis Toxicity
20 F 4 2 nil 172 Oesophagitis, myelosuppression, vomiting,
stomatitis Progression
21 B 3 2 CR 145 Myelosuppression, fever Progression
22 F 2 1 nil 608 Myelosuppression, mucositis, rash, vomiting Diagnosis changed
23 D 2 0 nil 887 + Vomiting Diagnosis changed
24 C 2 0 nil 37 Sudden collapse and death Death
'CR = complete response; PR = partial response; nil = stationary or progressive disease. b + ' indicates that the patient was still alive at the time of analysis.
in one because of toxicity, and in the fifth because of pro-
gressive disease. Treatment was thought to have been partly
or wholly responsible for death in all three who died during
the treatment period, all of whom came from different cen-
tres.
In contrast, of the 12 patients treated with cisplatin 80 mg
m-2, five received all their treatment and a further two all
except the last course of chemotherapy, which was omitted
because of toxicity. Of the remaining five, two had treatment
stopped because of progressive disease, and one patient col-
lapsed and died after the second course of chemotherapy
which was considered to be a contributory cause of death.
The remaining two had their treatment changed because, on
review of their histology after treatment had been started, the
diagnosis was changed: in one to carcinoid tumour, and in
the other to medullary carcinoma of the thyroid. In sum-
mary, the regimen with the lower cisplatin dosage was sub-
stantially more acceptable to patients.
Response to treatment
Among the 12 patients given the higher cisplatin dosage, a
complete response (CR) (Table II) was reported in seven and
a partial response (PR) in a further two. Moreover, one of
the patients with a partial response received only one course
of chemotherapy and one dose of radiotherapy. The remain-
ing three patients died without response, having received only
a single course of chemotherapy and no radiotherapy.
Among the ten patients with confirmed small-cell lung
cancer given the lower cisplatin dosage, a complete response
was reported in seven (in one of whom the disease subse-
quently progressed), and a partial response in one. The
remaining two patients failed to respond.
The total response rate was 17 (77%) of the 22 patients
with small-cell lung cancer (95% confidence interval 60 to
95%) and the complete response rate 14 (64%) (95% confi-
dence interval 44 to 84%).
Adverse effects
The analysis of adverse effects was based on all 24 patients,
including the two who were found not to have small-cell lung
cancer. The regimen, even with the reduced cisplatin dosage,
proved to be a demanding one for the patients, all of whom
experienced adverse effects, the clinically most important of
which are shown for each patient in Table II and by cisplatin
dosage in Table III. Myelosuppression was the commonest
serious adverse effect and gave rise to septicaemia in five of
the 24 patients, four of them being in the higher dose group.
Vomiting, oesophagitis, and peripheral neuropathy were also
common, being reported in 12, four and four patients respec-
tively, and radiation pneumonitis developed in two. Seven
patients on the higher cisplatin dosage compared with two on
the lower dosage had their treatment terminated prematurely
because of toxicity.
Haematological toxicity of WHO grade 2 or worse (Table
IV) was reported at routine assessment immediately before a
course of chemotherapy or radiotherapy in 17 of the 24
patients (left-hand section of the table), seven having grade 4
reactions. Additional blood counts were done, however, if778 N.M. BLEEHEN et al.
Table III Main adverse effects other than alopecia. WHO grade is
shown where applicable
Cisplatin dose (mgm-2)
Adverse effecta 100 80
Myelosuppression with:
no symptoms 2 5
septicaemia 3 1
septicaemia and bronchopneumonia 1 0
fever 3 1
oral candidiasis 0 1
oesophageal candidiasis 0 1
spontaneous bruising 1 0
Vomiting grade 2 4 4
grade 3 1 3
Oesophagitis 2 2
Peripheral neuropathy grade 1 0 3
grade 2 1 0
Mucositis grade 2 1 2
Impaired renal function grade 1 1 2
Cutaneous reaction grade 1 0 1
grade 2 0 2
Stomatitis grade 1 0 1
grade 2 0 1
Diarrhoea grade 2 0 2
Radiation pneumonitis 1 I
Jaundice grade 1 1 0
Sudden death 1 I
Total patients 12 12
'All except three ofthe patients receiving the higher dose and five the
lower dose experienced more than one type ofadverse effect.
TableIV Haematological toxicity ofWHO grade2orworse, bygrade
(World Health Organization, 1979). Based on all 12 patients with
cisplatin dose 100mgm-2 and all 12 with cisplatin dose 80mgm2
At routine assessments At any assessment
Cisplatin dose (mgm-2) Cisplatin dose (mgm-2)
Toxicity 100 80 100 80
Anaemia
grade 2 6 3 4 6
3 0 2 3 1
4 0 0 0 1
Leucopenia
grade 2 2 2 0 2
3 1 0 1 0
4 3 3 6 6
Thrombocytopenia
grade 2 2 0 1 1
3 1 1 0 1
4 2 2 7 5
Any toxicity
grade 2 4 4 1 2
3 1 1 0 0
4 4 3 9 7
The left-hand section shows patients with haematological toxicity at
routine assessments only. The right-hand section shows patients with
toxicity at any assessment, whether routine or not.
there was concern about a patient's progress. When these
additional results are included, haematological toxicity was
reported in 19 patients (right-hand section), 16 have grade 4
reactions. The numbers ofpatients with symptoms and infec-
tions attributed to myelosuppression are shown in Table III.
Sixteen patients (seven prescribed the higher and nine the
lower cisplatin dosage) were given one or more blood trans-
fusions, ten (four and six respectively) of the 16 also receiving
one or more platelet transfusions.
Although major adverse effects were equally common in
both groups of patients, the 12 prescribed the lower cisplatin
dosage received a higher proportion of their treatment (a
total of 53 courses, Table II) than the 12 prescribed the
higher dosage (39 courses). Toxicity was considered to be the
main or a contributory cause ofdeath in three of the patients
on the higher cisplatin dosage and in one on the lower
dosage.
Survival
Of the 22 patients with small-cell lung cancer, nine (41%)
were alive at 12 months (95% confidence interval 23-61%).
The median duration of survival from the start of treatment
was 308 days (95% confidence interval 248-554) and the
estimated survival at 2 years was 31% (95 % confidence
interval 16-52%). The duration of survival for each patient
is shown in Table II.
Discussion
This study has shown that when a regimen of alternating
chemothearpy and radiotherapy was used to treat small-cell
lung cancer in 22 patients with limited disease and good
performance staus, a complete response (World Health
Organization, 1979) was achieved in 14 (64%) and a partial
response in a further three. Nevertheless, major toxicity was
encountered in all 24 patients (including the two who were
withdrawn from the therapeutic analysis because histological
review showed their diagnosis to be incorrect). Thus, the
quality of survival during the treatment period was poor.
The commonest adverse reactions were those associated with
myelosuppression, namely septicaemia, fever, oral and
oesophageal candidiasis, bronchopneumonia, and bleeding
diathesis. Indeed, 16 of the 24 patients required blood trans-
fusion, and ten platelet transfusion. Oesophagitis, vomiting,
and peripheral neuropathy were also common, and radiation
pneumonitis developed in two patients. Moreover, treatment
was considered to have been a contributory cause of death in
four patients.
The first 12 patients were prescribed the regimen as report-
ed by Arriagada and his colleagues in France (Arriagada et
al., 1985a). But because of severe toxicity, only one of the 12
was able to complete the course. For the remaining patients
the dosage of cisplatin was therefore reduced from 100 to
80 mg m-2. This enabled most of them to complete or almost
complete the course, although their greater ability to tolerate
the regimen may be partly attributable to their somewhat
lower age distribution. Even so, major toxicity was still com-
mon with this reduced dose. It should be recognised that
patients admitted to a phase II trial tend to be a highly
selected group.
A possible explanation of why the regimen appeared to be
less toxic and more acceptable in the French study is that the
dose per square metre of each drug actually administered in
the first course of chemotherapy was substantially less than
the dose the protocol specified, namely 28% less for cyclo-
phosphamide, 18% for cisplatin, 20% for doxorubicin, and
13% for etoposide (Arriagada et al., 1989b).
In contrast, in the present study the protocol dosages were
closely adhered to, the mean of the dosages administered in
the first course of chemotherapy never falling below 98% of
the protocol dose.
Since, in the present study, the main adverse effects of
chemotherapy were related to neutropenia, it is possible that
they could be reduced in frequency and severity by giving
haemopoietic growth factor, such as granulocyte-colony-stim-
ulating-factor (G-CSF). This is currently under investigation.
In the present study, some complete responses were record-
ed in patients who received only three of the six courses of
chemotherapy and two or three of the three courses of
radiotherapy. This raises the question whether all six courses
of chemotherapy and all three of radiotherapy are necessary
to achieve a maximum response. The median survival period
was 308 days and the survival rates were 41% at 1 year and
31% at 2 years, results similar to those reported by Arria-
gada and his colleagues, although the corresponding 95%
confidence intervals are wide.
One of the main purposes of this study was to assess the
feasibility of using the alternating scheduling in the United
Kingdom. As a result of the high levels of toxicity and the
slow rate of intake, the MRC Lung Cancer Working Party
has decided that such scheduling is feasible in only a fewALTERNATING CHEMOTHERAPY AND RADIOTHERAPY IN SCLC 779
centres, and that a large multicentre randomised trial com-
paring alternating against conventional scheduling would be
unlikely to achieve a realistic rate of intake. This important
scientific comparison has yet to be made.
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